New Free DENSO Guide to Selecting Robots for Drug Discovery and Testing
DENSO Robotics Posted 02/02/2011DENSO Robotics announced publication of a new free guide, “Selecting Robots for Use in Drug Discovery and Testing: What Are the Essential Things to Know?”
“Robots have played a central role in drug discovery and testing for many years now,” said Peter Cavallo, robotics sales manager, DENSO Sales California. “The individuals at pharmaceutical companies who are involved in selecting robots are not usually engineers, however, so they need to become familiar with certain basic concepts in robot technology.”
The new eight page guide answers this need by examining key relevant aspects of Cartesian, four-axis SCARA and six-axis articulated robots. The guide is available as a free download from the DENSO Robotics Web site at www.densorobotics.com/pdf/drugdiscoveryandtesting (377 KB).
DENSO is the world’s largest user of small assembly robots, with more than 16,000 DENSO robots designed and used in its own manufacturing facilities. More than 60,000 DENSO robots are used in other companies worldwide. DENSO Robotics offers a complete line of robots, controllers and software covering a wide range of applications. For more information, visit www.densorobotics.com.
DENSO Corporation, headquartered in Kariya, Aichi prefecture, Japan, is a leading global automotive supplier of advanced technology, systems and components in the areas of thermal, powertrain control, electric, electronics and information and safety. Its customers include all the world's major carmakers. Worldwide, the company has more than 200 subsidiaries and affiliates in 34 countries and regions (including Japan) and employs approximately 120,000 people. Consolidated global sales for the fiscal year ending March 31, 2010, totaled US$32.0 billion. Last fiscal year, DENSO spent 9.1 percent of its global consolidated sales on research and development. DENSO common stock is traded on the Tokyo and Nagoya stock exchanges.
In the Americas, DENSO employs more than 16,000 people with consolidated sales totaling US$5.7 billion for the fiscal year ending March 31, 2010.